Mission Statement, Vision, & Core Values of PureTech Health plc (PRTC)

Ever wondered what drives a company dedicated to 'changing the lives of patients with devastating diseases'? What are the guiding principles behind PureTech Health's mission to develop innovative therapies? As of June 30, 2024, PureTech held $400.6 million in cash, cash equivalents, and short-term investments, and is expected to end 2024 with approximately $330 million in cash.

Do you know what values shape their culture and strategic decisions? Understanding a company's mission, vision, and core values provides critical insight into its long-term goals and how it operates. Read on to explore the foundational elements that define PureTech Health.

PureTech Health plc (PRTC) An Overview of

PureTech Health plc (PRTC) is a biopharmaceutical company dedicated to discovering, developing, and commercializing highly differentiated medicines for devastating diseases, including cancers, and immunological and neurological conditions. Founded with the vision of integrating cutting-edge science with entrepreneurial spirit, PureTech has evolved into a multifaceted enterprise, operating through its internal research and development programs and its Founded Entities.

PureTech Health operates primarily in the biopharmaceutical sector, focusing on creating and advancing novel medicines. The company's approach involves identifying unmet medical needs and then developing innovative solutions, often through its Founded Entities. These entities are independently operated but benefit from PureTech's strategic oversight and resources.

As of April 2025, specific, real-time sales figures for PureTech Health are subject to quarterly and annual financial reporting cycles. For the most up-to-date sales data, refer to PureTech Health's official investor relations releases and SEC filings. Recent reports often highlight key revenue streams from its portfolio companies and collaborations.

In the latest financial reports, PureTech Health has demonstrated significant financial performance. While exact figures fluctuate with ongoing developments, the company has consistently emphasized its strategic investments and clinical advancements as drivers of value. Keep an eye on their official releases for the most current data, typically found on their investor relations page.

Key highlights from recent financial reports include:

• Progress in clinical trials for lead candidates
• Strategic collaborations and partnerships
• Advancements in novel drug platforms

PureTech Health stands out as a pioneering biopharmaceutical company, driving innovation and creating value through its unique operating model. To delve deeper into the specifics of who invests in PureTech Health and the motivations behind those investments, explore: Exploring PureTech Health plc (PRTC) Investor Profile: Who’s Buying and Why?

PureTech Health plc (PRTC) Mission Statement

PureTech Health plc is a clinical-stage biotherapeutics company focused on discovering, developing, and commercializing medicines for devastating diseases. The company is dedicated to giving life to new classes of medicine to change the lives of patients. PureTech has a broad and deep pipeline being advanced both internally and through its Founded Entities.

The company's mission is supported by its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders. As of April 2025, PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval.

PureTech's commitment to sustainability is evident through its strong Environmental, Social, and Governance (ESG) practices. The company recognizes that maintaining a sustainable business is essential as it works to develop new medicines. PureTech participates in various third-party ESG Risk Ratings to evaluate its exposure to material industry-specific ESG risks. In 2023, they received positive ratings from Sustainalytics, ISS, CDP, and FTSE Russell.

PureTech's ESG framework focuses on three strategic areas:

• Patients: Commitment to good health and well-being.
• People: Promoting gender equality and decent work.
• Planet: Focusing on responsible climate action.

In April 2024, PureTech published its 4th edition of its ESG report, detailing its ESG strategy, performance, and ongoing progress. This report aligns its reporting with best practice frameworks including Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (SDGs), and the Task Force on Climate-related Financial Disclosures (TCFD) framework.

For more insights into PureTech Health plc, explore: PureTech Health plc (PRTC): History, Ownership, Mission, How It Works & Makes Money

PureTech Health plc (PRTC) Vision Statement

While a specific, formally declared vision statement for PureTech Health plc isn't readily available in my knowledge sources, we can analyze their mission, values, and strategic activities to infer their overarching vision. This inferred vision revolves around pioneering novel treatments for serious diseases by:

• Identifying and developing innovative technologies.
• Translating these technologies into impactful medicines.
• Building and financing a portfolio of affiliate companies to drive these advancements.

Let's explore the key elements that constitute this inferred vision.

Pioneering Novel Treatments

PureTech Health focuses on discovering, developing and commercializing highly differentiated medicines for devastating diseases. This is evident in their diverse pipeline and portfolio of affiliate companies, each targeting areas with significant unmet medical needs.

Innovative Technologies and Platforms

PureTech Health's vision emphasizes the importance of innovation as a driver for creating value. They seek to identify and advance groundbreaking technologies with the potential to address fundamental challenges in disease biology. This includes:

• LYT-100 (deupirfenidone): An anti-fibrotic and anti-inflammatory compound being evaluated for the potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions.
• LYT-200 (anti-CD122): A monoclonal antibody designed to deplete immunosuppressive IL-2Rβγ+ cells in the tumor microenvironment, currently in Phase 1/2 trials for solid tumors.

These technologies and platforms exemplify PureTech's commitment to innovation, attracting substantial investments and partnerships. For instance, in the fiscal year 2024, PureTech Health reported significant R&D investments totaling $174.1 million, reflecting their dedication to advancing these novel approaches.

Translating Technologies into Impactful Medicines

PureTech Health's vision extends beyond basic research to encompass the entire drug development lifecycle, with a focus on translating scientific discoveries into tangible benefits for patients. This involves:

• Conducting rigorous preclinical and clinical studies to evaluate the safety and efficacy of their drug candidates.
• Working closely with regulatory agencies to secure approvals and bring new medicines to market.
• Establishing partnerships with leading pharmaceutical companies to expand the reach and impact of their technologies.

Building and Financing a Portfolio of Affiliate Companies

A core element of PureTech Health's vision is its unique business model, which involves creating and nurturing a portfolio of affiliate companies. This approach allows them to:

• Focus on specific therapeutic areas or technology platforms through specialized entities.
• Attract dedicated management teams and investors to drive the growth of each affiliate.
• Realize value through strategic transactions, such as IPOs, mergers, or acquisitions.

As of the fiscal year 2024, PureTech Health held equity positions in several key affiliates, including:

• Karuna Therapeutics: Acquired by Bristol Myers Squibb for $14 billion.
• Vor Biopharma: A clinical-stage cell and gene therapy company.

These affiliates represent a diverse range of therapeutic areas and modalities, reflecting PureTech Health's broad vision for addressing unmet medical needs.

For more insights into PureTech Health's financial strategy, see: Breaking Down PureTech Health plc (PRTC) Financial Health: Key Insights for Investors

PureTech Health plc (PRTC) Core Values of

While specific, formally published core values for PureTech Health plc are not readily available, we can infer key values from their stated mission, strategic priorities, and activities. These inferred values emphasize innovation, collaboration, and a commitment to addressing significant unmet needs in healthcare.

Commitment to Innovation

PureTech Health operates with a focus on pioneering approaches to address challenging diseases. This commitment is evident in their approach to creating and advancing novel medicines. For example, PureTech Health's founded entities and programs reflect this value by targeting areas where current treatments are inadequate or non-existent. The company's pipeline includes projects focused on immunomodulation, lymphatic system targeting, and novel drug delivery platforms, all representing innovative approaches to therapeutic development. This dedication to innovation is also reflected in their financial strategy, with substantial investments in research and development aimed at bringing groundbreaking therapies to market. PureTech's R&D expenses were $146.9 million for the year ended December 31, 2024, compared to $138.0 million for the year ended December 31, 2023.

Collaboration and Partnership

Collaboration is central to PureTech Health's business model. They actively form partnerships with leading academic institutions, research organizations, and other biotechnology companies to leverage expertise and resources. This collaborative approach is crucial for sharing risks and accelerating the development of new medicines. For instance, PureTech often collaborates with universities to license promising technologies or co-develop therapies. These partnerships not only enhance their research capabilities but also facilitate access to cutting-edge science and talent. A strong example of this is their relationship with various scientific advisory boards and key opinion leaders who provide guidance and support for their programs. In 2024, PureTech Health's collaborations contributed significantly to the advancement of several pipeline programs, demonstrating the practical benefits of their partnership-focused strategy.

Focus on Unmet Needs

A core value for PureTech Health is addressing significant unmet needs in healthcare. This is demonstrated by their strategic focus on developing therapies for diseases with limited or no effective treatments. Their pipeline is populated with programs targeting conditions such as lymphedema, inflammatory diseases, and certain types of cancer, reflecting a commitment to areas where patients have few options. This focus extends beyond just developing new drugs; it includes a commitment to improving patient outcomes and quality of life. For example, PureTech’s investment in therapies that aim to modulate the immune system reflects a response to the growing need for more effective treatments for autoimmune diseases. This commitment is also seen in their approach to drug development, which emphasizes personalized medicine and targeted therapies designed to address the specific needs of patient populations. As of 2024, PureTech Health has continued to prioritize these areas, allocating significant resources to programs that promise to deliver meaningful benefits to patients with severe and difficult-to-treat conditions.

Scientific Rigor and Excellence

PureTech Health emphasizes scientific rigor and excellence in all its endeavors. This commitment is reflected in their approach to research and development, which is characterized by a strong emphasis on data-driven decision-making and adherence to the highest scientific standards. The company employs a team of experienced scientists and clinicians who bring deep expertise to their respective fields. This dedication to scientific rigor is evident in their clinical trial designs, which are carefully crafted to ensure the safety and efficacy of their therapies. Furthermore, PureTech actively participates in scientific conferences and publishes their research findings in peer-reviewed journals, contributing to the broader scientific community and fostering transparency. In 2024, PureTech Health continued to uphold these standards, ensuring that all their programs are grounded in sound scientific principles and rigorous testing.

To delve deeper into PureTech Health, explore: PureTech Health plc (PRTC): History, Ownership, Mission, How It Works & Makes Money